This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Takeshita, S. Articles by Tokutomi, T. Search for Related Content PubMed PubMed Citation Articles by Takeshita, S. Articles by Tokutomi, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Kawasaki Disease Hazardous Substances DB PREDNISOLONE Social Bookmarking                   What's this?

Standard-dose and Short-term Corticosteroid Therapy in Immunoglobulin-resistant Kawasaki Disease

University of Shizuoka, Junior College, Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan

Youichi Kawamura, MD

Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan

Keigo Nakatani, MD, PhD

Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan

Hiroshi Tsujimoto, MD, PhD

Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan

Tomoharu Tokutomi, MD

Department of Pediatrics, National Defense Medical College, Tokorozawa, Saitama 359-8513, Japan

Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose). Five patients responded immediately to the first course of prednisolone infusion. One patient failed to respond to the first course of prednisolone therapy, but he did respond to the second 3-day course of therapy. None of the patients demonstrated a further progression of coronary artery dilatation or any adverse effects. Standard-dose and short-term corticosteroid therapy therefore appears to be a safe and effective treatment for patients with IVIG-resistant KD.

Clinical Pediatrics, Vol. 44, No. 5, 423-426 (2005)
DOI: 10.1177/000992280504400507


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. J. O'Connor and F. T. Saulsbury Incomplete and Atypical Kawasaki Disease in a Young Infant: Severe, Recalcitrant Disease Responsive to Infliximab Clinical Pediatrics, May 1, 2007; 46(4): 345 - 348. [Abstract] [PDF]